Camber Pharmaceuticals continues to expand its portfolio of treatment options with the launches of Plerixafor Injection, Baclofen Tablets, Fluvoxamine Maleate ER Capsules, and Olmesartan Hydrochlorothiazide Tablets.
| Product | Brand Reference | Strength/Size |
| Plerixafor Injection
[pler-IX-a-fore] |
Mozobil® | 24 mg/1.2 mL (20 mg/mL) |
| Baclofen Tablets
[BAK-loe-fen] |
Lioresal® | 100 ct bottles of 5, 10, & 20 mg 1,000 ct bottles of 10 & 20 mg |
| Fluvoxamine Maleate ER Capsules
[floo-VOX-a-meen] |
Luvox® | 30 ct bottles of 100 & 150 mg |
| Olmesartan and Hydrochlorothiazide Tablets
[ol-me-SAR-tan and HYE-droe-KLOR-oh-THYE-a-zide] |
Benicar® HCT | 30 & 90 ct bottles of 20 mg/12.5 mg 30 & 90 ct bottles of 40 mg/12.5 mg 30 & 90 ct bottles of 40 mg/25 mg |
These additions reinforce Camber’s commitment to broadening access to affordable, high-quality therapies while continuing to support patients and healthcare professionals nationwide.
